Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study

References

• Andersson GB. Epidemiological features of chronic low-back pain. Lancet 1999;354:581-5
   PubMed Web of Science ®Google Scholar
• Frymoyer JW. Back pain and sciatica. N Engl J Med 1988;318:291-300
   PubMed Web of Science ®Google Scholar
• Lawrence VA, Tugwell P, Gafni A, et al. Acute low back pain and economics of therapy: the iterative loop approach. J Clin Epidemiol 1992;45:301-11
   PubMed Web of Science ®Google Scholar
• van Tulder MW, Koes BW, Bouter LM, Tulder van MW. A cost-of-illness study of back pain in The Netherlands. Pain 1995;62:233-40
   PubMed Web of Science ®Google Scholar
• Wenig CM, Schmidt CO, Kohlmann T, Schweikert B. Costs of back pain in Germany. Eur J Pain 2009;13:280-6
   PubMed Web of Science ®Google Scholar
• van Tulder M, Koes BW. Low back pain. Am Fam Physician 2002;65:925-8
   PubMed Web of Science ®Google Scholar
• Cassidy JD, Cote P, Carroll LJ, et al. Incidence and course of low back pain episodes in the general population. Spine 2005;30:2817-23
   PubMed Web of Science ®Google Scholar
• Manek NJ, MacGregor AJ. Epidemiology of back disorders: prevalence, risk factors, and prognosis. Curr Opin Rheumatol 2005;17:134-40
   PubMed Web of Science ®Google Scholar
• Deyo RA, Weinstein JN. Low back pain. N Engl J Med 2001;344:363-70
   PubMed Web of Science ®Google Scholar
• Borenstein D. Chronic low back pain. Musculoskeletal Med 1996;22:439-56
   Google Scholar
• Pincus T, Burton AK, Vogel S, et al. A systematic review of psychological factors as predictors of chronicity/disability in prospective cohorts of low back pain. Spine 2002;27:E133-8
   PubMedGoogle Scholar
• Kent PM, Keating JL, Buchbinder R. Searching for a conceptual framework for nonspecific low back pain. Man Ther 2009;14:387-96
   PubMed Web of Science ®Google Scholar
• Airaksinen O, Brox JI, Cedraschi C, et al.;COST B13 Working Group on Guidelines for Chronic Low Back Pain. European guidelines for the management of chronic non-specific low back pain. Eur Spine J 2006;15(Suppl 2):S192-300
   PubMed Web of Science ®Google Scholar
• Chou R, Huffman LH; American Pain Society; American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007;147:505-14
   PubMed Web of Science ®Google Scholar
• Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie Kreuzschmerz – Langfassung. Version 1.2, 2010. Available at: http://www.versorgungsleitlinien.de/themen/kreuzschmerz) [Last accessed 26 June 2012]
   Google Scholar
• Deshpande A, Furlan A, Mailis-Gagnon A, et al. Opioids for chronic low back pain. Cochrane Database Syst Rev 2007;3, CD004959 (doi: 10.1002/14651858.CD004959.pub3)
   PubMed Web of Science ®Google Scholar
• Roelofs PD, Deyo RA, Koes BW, et al. Nonsteroidal anti-inflammatory drugs for low back pain. Spine 2008;33:1766-74
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Ferraro A, Hunsche E, et al. A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain. J Pain Symptom Manage 2004;28:72-95
   PubMed Web of Science ®Google Scholar
• Martell BA, O’Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 2007;146:116-27
   PubMed Web of Science ®Google Scholar
• Koes BW, Scholten RJ, Mens JM, et al. Efficacy of non-steroidal anti-inflammatory drugs for low back pain: a systematic review of randomized clinical trials. Ann Rheum Dis 1997;56:214-23
   PubMed Web of Science ®Google Scholar
• Cepeda MS, Camargo F, Zea C, et al. Tramadol for osteoarthritis: a systematic review and metaanalysis. J Rheumatol 2007;34:543-55
   PubMed Web of Science ®Google Scholar
• Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992;327:749-54
   PubMed Web of Science ®Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99
   PubMed Web of Science ®Google Scholar
• Ueberall MA, Mueller-Schwefe GHH, Terhaag B. Efficacy and tolerability of flupirtine in subacute/chronic musculoskeletal pain – results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials. Int J Clin Pharmacol Therapeut 2011;49:637-47
   PubMed Web of Science ®Google Scholar
• Li C, Ni J, Wang Z, et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008;24:3523-30
   Google Scholar
• International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance. Available at: http://www.fda.gov/downloads/regulatoryinformation/guidance’s/ucm129515.pdf [Last accessed 23 July 2012]
   Google Scholar
• Müller-Schwefe G, Zenz M (eds). The German Pain Questionnaire. German Pain Association, 2006. ISBN: 3-00-017-440-0
   Google Scholar
• Ware JE Jr, Kosinski M, Keller SD. A 12 Item Short Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33
   PubMed Web of Science ®Google Scholar
• Überall MA, Müller-Schwefe GHH. Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice. Curr Med Res Opin 2012;28:1-9
   Web of Science ®Google Scholar
• Babul N, Noveck R, Chipman H, et al. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004;28:59-71
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Gray WL, Paster RZ, et al. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol 2000;27:772-8
   PubMed Web of Science ®Google Scholar
• Malonne H, Coffiner M, Sonet B, et al. Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004;26:1774-82
   PubMed Web of Science ®Google Scholar
• Arnold R. Why patients do not take their opioids. J Palliat Med 2004;7:716-17
   PubMedGoogle Scholar
• Bhamb B, Brown D, Hariharan J, et al. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin 2006;22:1859-65
   PubMed Web of Science ®Google Scholar
• Gureje O, Von KM, Simon GE, Gater R. Persistent pain and well-being: a world health organization study in primary care. JAMA 1998;280:147-51
   PubMed Web of Science ®Google Scholar
• Becker N, Bondegaard Thomsen A, Olsen AK, et al. Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center. Pain 1997;73:393-400
   PubMed Web of Science ®Google Scholar
• Ashburn MA, Staats PS. Management of chronic pain. Lancet 1999;353:1865-9
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58
   PubMed Web of Science ®Google Scholar
• Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 2005;6:21-8
   PubMed Web of Science ®Google Scholar
• Hale ME, Ahdieh H, Ma T, Rauck R. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007;8:175-84
   PubMed Web of Science ®Google Scholar
• Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 2005;6:357-66
   PubMed Web of Science ®Google Scholar
• Minami K, Uezono Y, Ueta Y. Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J Pharmacol Sci 2007;103:253-60
   PubMed Web of Science ®Google Scholar
• Szelenyi I, Nickel B. Putative site(s) and mechanism(s) of action of flupirtine, a novel analgesic compound. Postgrad Med J 1987;63(Suppl 3):57-60
   PubMedGoogle Scholar
• Jakob R, Krieglstein J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurones. Br J Pharmacol 1997;122:1333-8
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Bleich S, Wiltfang J, et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication. J Neural Transm 1999;106:857-67
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Maler M, Wiltfang J, et al. Neuronal potassium channel opening with flupirtine. Fortschr Neurol Psychiatr 1999;67:466-75
   PubMed Web of Science ®Google Scholar
• Methling K, Reszka P, Lalk M, et al. Investigation of the in vitro metabolism of the analgesic flupirtine. Drug Metab Dispos 2009;37:479-93
   PubMed Web of Science ®Google Scholar
• Miceli F, Soldovieri MV, Martire M, Taglialatela M. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. Curr Opin Pharmacol 2008;8:65-74
   PubMed Web of Science ®Google Scholar
• Wörz R, Bolten W, Heller B, et al. Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study. Fortschr Med 1996;114:500-4
   PubMedGoogle Scholar
• Müller-Schwefe GHH, Überall MA. Analgesic and muscle tonus normalizing effect of flupirtine retard in chronic back pain. Results of a standardized therapeutic evaluation applying objective methods for measuring pain pressure threshold, pain pressure tolerance and muscle tension. MMW Fortschr Med 2008;149(Suppl 4):153-61
   PubMedGoogle Scholar
• Radbruch L, Grond S, Lehmann KA. A risk–benefit assessment of tramadol in the management of pain. Drug Saf 1996;15:8-29
   PubMed Web of Science ®Google Scholar
• T-long. Summary of product characteristics. AWD.pharma GmbH & Co. KG; Dec 2008
   Google Scholar
• Katadolon S long. Summary of product characteristics. AWD.pharma/CT Arzneimittel GmbH; May 2012
   Google Scholar
• McCarberg B. Tramadol extended-release in the management of chronic pain. Ther Clin Risk Manag 2007;3:401-10
   PubMedGoogle Scholar
• Vorsanger GJ, Xiang J, Gana TJ, et al. Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid Manag 2008;4:87-97
   PubMedGoogle Scholar
• Dworkin RH, Turk DC, Peirce-Sandner S, et al. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 2010;149:177-93
   PubMed Web of Science ®Google Scholar
• Mattia C, Coluzzi F. Tramadol. Focus on musculoskeletal and neuropathic pain. Minerva Anestesiol 2005;71:565-84
   PubMedGoogle Scholar
• Choi CB, Song JS, Kang YM, et al. A 2-week, multicenter, randomized, double-blind, double dummy, add-on study of the effects of titration on tolerability of tramadol/acetaminophen combination tablet in Korean adults with knee osteoarthritis pain. Clin Ther 2007;29:1381-9
   PubMed Web of Science ®Google Scholar
• Tagarro I, Herrera J, Barutell C, et al. Effect of a simple dose-escalation schedule on tramadol tolerability: assessment in the clinical setting. Clin Drug Investig 2005;25:23-31
   PubMed Web of Science ®Google Scholar
• Ruoff GE. Slowing the initial titration rate of tramadol improves tolerability. Pharmacotherapy 1999;19:88-93
   PubMed Web of Science ®Google Scholar
• Petrone D, Kamin M, Olson W. Slowing the titration rate of tramadol HCl reduces the incidence of discontinuation due to nausea and/or vomiting: a double-blind randomized trial. J Clin Pharm Ther 1999;24:115-23
   PubMed Web of Science ®Google Scholar
• O’Donnel JB, Ekman EF, Spalding WM, et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res 2009;37:1789-802
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21
   PubMed Web of Science ®Google Scholar